Compare ARK Innovation ETF (ARKK) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Charles River Laboratories Intl. Inc — how do they compare? ARK Innovation ETF trades at $81.39, while Charles River Laboratories Intl. Inc trades at $286.79 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | CRL | |
|---|---|---|
52-Week High | $92.50 | $282.00 |
52-Week Low | $63.52 | $145.57 |
Market Cap | — | $13.46B |
Sector | — | Health |
Enterprise Value | — | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.22, up 0.94% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF's concentrated portfolio in disruptive innovation faces mixed sentiment, with recent news highlighting both buying activity in AI stocks like CoreWeave and concerns over high fees and underperformance versus the S&P 500. Key resistance is at $82, with support at $79.
Outlook remains volatile; ARKK offers exposure to high-growth themes like AI and space technology but carries significant concentration risk and fee drag. Investment opportunity hinges on successful bets in unprofitable ventures, while risks include dependency on Tesla and SpaceX performance and broader market shifts away from speculative growth.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
